Joanna Strober stood before an audience in San Francisco on April 15, 2026, to detail how Midi Health reached a $1 billion valuation by shifting its core identity from a medical provider to an artificial intelligence firm. Jason Blum later joined the conversation to discuss how Blumhouse transitioned into AI experimentation despite facing serious public criticism. These two leaders represent a growing divide in how corporate entities integrate generative tools into their business models. While one finds success in automating clinical expertise, the other discovers the limitations of digital creativity in the horror genre.
Midi Health, based in Palo Alto, California, provides virtual care to menopausal women and recently crossed the billion-dollar threshold in a February funding round. Strober told the audience at the Long Play event that her original vision for a menopause company evolved into a technology-first operation. The necessity of this shift became apparent when the company attempted to scale its services to meet huge demand. Human providers alone could not maintain the pace required to serve 20,000 women per week.
Scaling healthcare requires more than hiring additional staff. Training providers on the complexities of menopause proved difficult because medical research in this specific field is notoriously sparse. General-purpose AI models often failed to provide accurate or safe answers because they were trained on a wide internet full of outdated studies. Strober realized her firm could not rely on open-market solutions like ChatGPT for patient-facing interactions.
Midi Health Scaling and Growth Logistics
Data integrity became the primary hurdle for the Palo Alto startup. Much of the publicly available data regarding hormone replacement therapy and menopause has been disproven by modern longitudinal studies. Relying on an AI that might hallucinate medical advice from a 1990s blog post presented an unacceptable risk to patient safety. So, the engineering team built a proprietary system restricted to high-quality, verified medical data. This narrow focus ensured the chatbot would not recycle discarded myths about women's health.
The internal deployment of these tools changed the daily operations for thousands of healthcare providers. Strober spends meaningful time traveling across the United States to meet with nurses and explain how these digital assistants function. She emphasized that the goal is not to replace the human element of care but to handle the administrative and informational load that leads to clinician burnout. A single nurse managing hundreds of contracts can now complete tasks in minutes that previously required a full month of manual labor.
Contracts that once sat in piles now move through Google Gemini for standardization. One specific nurse reported that a project intended to last thirty days took only ten minutes after she applied the internal AI tool. Such efficiency gains are the engine behind the $1 billion valuation. Investors see the potential for a medical firm to operate with the lean margins of a software company. Strober confirmed the company now services millions of women annually.
Internal AI Pivot and Efficiency Gains
Operational shifts at Midi Health extend into weekly office hours where staff members share their own discoveries in AI usage. These sessions allow the company to crowdsource innovation from the ground up. Instead of a top-down mandate, the nurses and administrators find their own ways to apply the technology to their specific bottlenecks. The company culture has shifted toward a constant state of iteration. Success in this sector is measured by the speed of accurate delivery.
Healthcare remains a field where accuracy is the only currency that matters. Unlike creative industries, there is no room for "hallucination" or artistic flair in a prescription or a diagnostic recommendation. The rigid nature of medical protocols makes it an ideal candidate for highly constrained AI models. Strober maintains that the human provider is the ultimate arbiter, but the AI is the librarian and the administrator. The market response to this hybrid model suggests that the future of specialized medicine lies in these bespoke digital frameworks.
While healthcare sees a clear path toward automation, the creative arts face a more volatile environment. Jason Blum, the founder and CEO of Blumhouse Productions, entered the AI space through a partnership with Meta in October 2024. The move was designed to test how generative video models could assist in the filmmaking process. Blumhouse has a reputation for high-efficiency, low-budget horror hits like Paranormal Activity and Get Out, making it a logical partner for experimental tech.
Blumhouse Production Backlash and Development
Public reaction to the Meta partnership was swift and negative. Users on social media platforms criticized the move as a betrayal of human artists and writers. Blum acknowledged the intensity of this backlash during his appearance in San Francisco. He noted that the experience of being "destroyed" on Twitter taught him valuable lessons about the current state of the technology. The experiment did not result in the immediate replacement of his production crews.
AI is not going to be making better content than our directors and writers for a long, long time, but it will change the way creators work on social media.
Experiments with three short films for Meta revealed the current limitations of generative video. The output lacked the emotional depth and narrative cohesion required for a feature-length cinematic experience. Blum noted that the uncanny nature of current AI clips, such as fake footage of movie stars, does not translate to effective storytelling. The king of modern horror expressed confidence that human directors are safe from digital obsolescence for the foreseeable future. The craft of filmmaking involves too many variables for a current model to replicate.
The real threat, according to Blum, is not to Hollywood directors but to online content creators. People who produce short-form videos for social media platforms face direct competition from generative tools. Those creators must now compete with algorithms that can produce infinite streams of engaging, low-context visual material. A movie theater experience offers something structurally different from the endless scroll of a smartphone screen. Blumhouse continues to focus on theatrical releases like Lee Cronin's The Mummy.
Growth Prospects for Cinematic Creators
Directorial vision and human performance are the elements that AI struggles to mimic most. While a computer can generate a jump scare, it cannot yet understand the psychological tension that makes a horror film resonate with a global audience. The creative process at Blumhouse still centers on the writer and the director. Blum argues that the tools will eventually find a place in the post-production pipeline, helping with visual effects or background rendering. These applications are more about cost reduction than creative replacement.
The economic reality of Hollywood requires a constant search for efficiency. Rising production costs have pushed many studios to look for ways to trim budgets without sacrificing quality. If AI can handle the tedious aspects of color grading or digital cleanup, it frees up resources for the actual storytelling. Blumhouse has always operated on a model of disciplined spending. Using technology to maintain that discipline is a natural extension of the company's founding philosophy. The Meta partnership is a testing ground for these future efficiencies.
Market analysts are watching the divergence between the healthcare and entertainment sectors closely. In medicine, AI is a tool of expansion and accuracy. In film, it is currently a tool of controversy and cost-cutting. Two paths may never converge. A doctor needs a facts-only machine, whereas a filmmaker needs a machine that understands the detail of human fear. Current large language models are considerably better at the former than the latter. The success of Midi Health suggests that the most profitable AI applications are those that fix broken informational systems.
The Elite Tribune Strategic Analysis
Conventional wisdom suggests that artificial intelligence will eventually swallow both the artist and the physician, yet the evidence from Midi Health and Blumhouse reveals a much more fragmented reality. The trend line shows the death of the generalist AI and the birth of the hyper-specialized engine. Joanna Strober did not find success by using a broad tool; she found it by surgically removing the "open" part of the internet from her database. This is a damning indictment of the current state of public AI.
If the sum total of human digital knowledge is too polluted with misinformation to help a menopausal woman, then the primary value of AI lies in its ability to ignore the majority of what it has learned.
Jason Blum's experience with Meta exposes the creative industry's most uncomfortable truth. The fear of AI replacing directors is a distraction from the fact that most digital "content" is already disposable. If an algorithm can replace a social media creator, it is because that creator was already producing algorithmic output. Cinema survives because it is difficult, expensive, and deeply human. The moment a film becomes mere "content" for a feed, it loses its immunity to the machine. Leaders who prioritize high-integrity data over high-volume noise will be the ones left standing. Accuracy is a moat. Creativity is a fortress. Everything in between is up for grabs.